Novel Claims-Based Algorithm Identifies Patients With PAH 6 Months Before Diagnosis
June 23rd 2023The model has potential to assist integrated delivery network health care providers through early identification of patients with pulmonary arterial hypertension (PAH), a rare but fast-progressing condition.
Read More
Signs of Depression Linked to mAb Therapy Nonresponse in Patients With Severe Asthma
June 23rd 2023A recent study found that depressive symptoms improved among patients with severe asthma who responded to monoclonal antibody (mAb) therapy, but baseline depression symptoms were associated with lower therapy response rates.
Read More
NCCN Adds Epcoritamab to Clinical Practice Guidelines in Oncology for DLBCL
June 23rd 2023Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma.
Read More
Exercise Rehabilitation Found to Help Alleviate Symptoms of Several Chronic Respiratory Diseases
June 23rd 2023Researchers discovered that exercise helps to alleviate various symptoms for patients with chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis, interstitial lung disease, and lung cancer.
Read More
Earlier Use of CAR T Cells Holds Promise in Blood Cancers, but Access Remains an Issue
June 23rd 2023A panel of experts at the American Society of Clinical Oncology Annual Meeting presented the latest research and equity considerations for chimeric antigen receptor (CAR) T-cell therapy in hematological cancers.
Read More
FDA Pauses Upifitamab Rilsodotin Trials in Platinum-Sensitive Ovarian Cancer
June 23rd 2023Following safety reports of bleeding events after treatment with upifitamab rilsodotin among patients with platinum-sensitive ovarian cancer, the FDA places a partial clinical hold on enrollment for the UP-NEXT and UPGRADE-A trials.
Read More
At 5 Years, Data Affirm Durability of Axi-Cel Response in Refractory LBCL
June 22nd 2023Considering the depth and durability of responses with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL), the investigators added that CAR T cells should no longer be seen as a therapy only for heavily pretreated patients, but also as an option for earlier lines of therapy.
Read More
Better Data Is Needed to Tackle Health Equity
The US federal government is finally updating its standards for reporting data on race and ethnicity – and it’s an urgently needed chance to enable a national overview of crucial data on health inequities
Read More
ASCO, ESMO Panel Highlights Progress and Disparities in Lung and Colorectal Cancer Screening
June 22nd 2023A session chaired by ASCO and ESMO leadership included experts on the latest lung and colorectal cancer screening technologies and persistent disparities in screening access and uptake.
Read More
New Epcoritamab Data Show Strong Results in B-Cell Lymphomas
June 22nd 2023Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.
Read More
Dr Andy Blauvelt: Drug Approval, Accessibility Challenges in Treating Patients With AD
June 22nd 2023Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses challenges many physicians face in getting approved for the most effective drugs to treat patients with atopic dermatitis (AD).
Watch
COPD in Patients With Type 2 Diabetes Associated With Increased Overall, Respiratory Mortality
June 21st 2023Researchers found that those with both type 2 diabetes and chronic obstructive pulmonary disease (COPD) had lower all-cause and respiratory-cause mortality survival probabilities than those without COPD.
Read More
FDA Approves Jardiance, Synjardy for Pediatric T2D
June 21st 2023Yesterday’s FDA approvals of a new indication for empagliflozin and combination empagliflozin with metformin hydrochloride for pediatric type 2 diabetes (T2D) provide a new class of oral drugs to treat the condition in children.
Read More